Overview

About

STORM Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications to treat disease. Its world leading understanding of RNA modifying enzymes (RME) has led to the discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases. Fierce Biotech named STORM as one of its 2022 “Fierce 15”, designating it as one of the most innovative, exciting biotechnology companies in the industry, pioneering novel drug targets.

STC-15

STORM’s lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being evaluated in a Phase 1b/2 study in combination with LOQTORZI™ toripalimab-tpzi in patients with non-small cell lung cancer, squamous cell cancer of the head and neck, melanoma, and endometrial cancer.

Final clinical results from a Phase 1 study of STC-15 in patients with advanced malignancies demonstrated that it is well tolerated and achieved tumor regressions at all dose levels evaluated, with an overall response rate of 9% and disease control rate of 67% as a monotherapy treatment. Pharmacokinetic simulations and safety data support advancing STC-15 into combination studies with checkpoint inhibitors, such as LOQTORZI.

Preclinical data have revealed that METTL3 inhibition has anti-tumor effects through multiple mechanisms of action, including the upregulation of PD-L1 expression, leading to T-cell mediated tumor cell killing.